There is currently no cure for FSGS, which is the leading cause of kidney failure in children, and 5,400 patients are ...

Adam Townsend, chief operating officer, has decided to pursue a new opportunity as a chief executive officer at a private biotechnology company and will depart Apellis on February 21, 2025. Since ...

Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney DiseasePlans to Initiate Rare Kidney Diseases Cohort in Early ...

This week’s Bulls N’ Bears Runner of the Week is … Sparc Technologies. The company is developing new-age hydrogen technology ...

Dimerix Ltd. and Fuso Pharmaceutical Industries Ltd. signed a license agreement for the development and commercialization of Dimerix’s phase III candidate, DMX-200, for the treatment of focal ...

Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and ...

Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced ...

Dimerix has entered an exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-200 in ...

Biopharmaceutical company Dimerix Ltd (ASX:DXB) has partnered with Japanese company FUSO to progress the development and ...

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

In morning trade, the ASX healthcare stock is up 31% to 46.5 cents. Investors have been fighting to get hold of the ...

Request To Download Free Sample of This Strategic Report @ This country research report on Vietnam Insulin Pumps Market offers comprehensive insights into the market landscape, customer intelligence, ...